SK Plasma Launches 'Revolpak', a Platelet Disorder Treatment
"Expanding Beyond Blood Disorders
to Rare and Intractable Disease Treatments"
SK Plasma has expanded its portfolio to include treatments for rare and severe blood disorders.
On August 3, SK Plasma announced that it will begin supplying 'Revolpak Tablets 25·50mg', which received product approval from the Ministry of Food and Drug Safety in May, to the domestic market in earnest.
Revolpak is a prescription thrombocytopenia treatment containing eltrombopag olamine. Eltrombopag olamine works by promoting platelet production in the bone marrow to increase platelet count, and it is used in the treatment of chronic immune thrombocytopenia and severe aplastic anemia.
SK Plasma has expanded its portfolio of treatments for rare and severe blood disorders to include not only hemophilia therapies but also Revolpak, leveraging its accumulated expertise and supply capabilities in the field of blood products. The company stated that it will continue to secure and supply essential medications for patient care moving forward.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim Seungjoo, CEO of SK Plasma, stated, "Even if the number of patients is small, every new treatment option is important for those who need therapies for rare and intractable diseases. Based on our expertise in the field of blood disorders, we will broaden patient choices within blood-related therapeutics and expand our business into all areas of rare and intractable diseases where treatments have yet to be developed."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.